NASDAQ:CGEN - Compugen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.30 +0.10 (+3.13 %)
(As of 07/15/2018 04:00 PM ET)
Previous Close$3.30
Today's Range$3.15 - $3.40
52-Week Range$2.25 - $5.00
Volume132,682 shs
Average Volume275,863 shs
Market Capitalization$169.27 million
P/E Ratio-4.58
Dividend YieldN/A
Beta0.26
Compugen logoCompugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGEN
CUSIPN/A
Phone972-3765-8585

Debt

Debt-to-Equity RatioN/A
Current Ratio5.81
Quick Ratio5.81

Price-To-Earnings

Trailing P/E Ratio-4.58
Forward P/E Ratio-7.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$710,000.00
Price / Sales238.39
Cash FlowN/A
Price / CashN/A
Book Value$0.57 per share
Price / Book5.79

Profitability

EPS (Most Recent Fiscal Year)($0.72)
Net Income$-37,060,000.00
Net MarginsN/A
Return on Equity-78.00%
Return on Assets-62.61%

Miscellaneous

Employees101
Outstanding Shares51,290,000
Market Cap$169.27

The Truth About Cryptocurrencies

Compugen (NASDAQ:CGEN) Frequently Asked Questions

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) posted its earnings results on Tuesday, August, 2nd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.04. The biotechnology company earned $0.50 million during the quarter, compared to analysts' expectations of $0.11 million. View Compugen's Earnings History.

When is Compugen's next earnings date?

Compugen is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Compugen.

What price target have analysts set for CGEN?

2 Wall Street analysts have issued 1 year price targets for Compugen's shares. Their forecasts range from $9.00 to $9.00. On average, they expect Compugen's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 172.7% from the stock's current price. View Analyst Ratings for Compugen.

What is the consensus analysts' recommendation for Compugen?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Compugen's key competitors?

Who are Compugen's key executives?

Compugen's management team includes the folowing people:
  • Dr. Anat Cohen-Dayag, Chief Exec. Officer, Pres and Director (Age 51)
  • Mr. Ari Krashin, Chief Financial and Operating Officer (Age 45)
  • Mr. Kirk A. Christoffersen MBA, Sr. VP of Corp. and Bus. Devel. (Age 49)
  • Dr. Zurit Levine Ph.D., VP of Research & Discovery (Age 50)
  • Dr. John J. Hunter, VP of Antibody R&D (Age 55)

Has Compugen been receiving favorable news coverage?

Media headlines about CGEN stock have trended somewhat positive on Sunday, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Compugen earned a coverage optimism score of 0.05 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 43.00 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $3.30.

How big of a company is Compugen?

Compugen has a market capitalization of $169.27 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-37,060,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Compugen employs 101 workers across the globe.

How can I contact Compugen?

Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]


MarketBeat Community Rating for Compugen (NASDAQ CGEN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  368
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.